Financial Lp Hrt Purchases 25,836 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 25,836 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were acquired at an average price of $3.44 per share, for a total transaction of $88,875.84. Following the transaction, the insider owned 71,842 shares in the company, valued at approximately $247,136.48. This represents a 56.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.23 per share, with a total value of $21,818.65.

Shuttle Pharmaceuticals Stock Performance

Shares of Shuttle Pharmaceuticals stock traded up $0.15 during trading on Wednesday, reaching $3.40. 169,219 shares of the company’s stock were exchanged, compared to its average volume of 2,351,062. The company has a market cap of $2.18 million, a P/E ratio of -0.07 and a beta of 0.29. The firm’s 50-day moving average price is $5.93 and its 200 day moving average price is $10.74. Shuttle Pharmaceuticals Holdings, Inc. has a 1-year low of $2.90 and a 1-year high of $55.90.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

Several institutional investors have recently made changes to their positions in SHPH. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the third quarter worth $357,000. Geode Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Boothbay Fund Management LLC bought a new position in Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter valued at $124,000. Institutional investors own 4.58% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .